User login
Dr James de Lemos, professor of internal medicine at the University of Texas Southwestern Medical Center, presents a framework to address the most common questions that patients have about the reported muscular, cognitive, and hepatotoxic side effects of statin therapy.
To start, he presents clinical data to address areas of patient concern. Next, he discusses ways to develop — from the first visit — a partnership with patients and encourage their informed decision-making by guiding them to reliable medical sources.
Finally, Dr de Lemos presents strategies that clinicians can use to improve adherence to statin therapy to reach LDL-C treatment goals
--
James de Lemos, MD, PhD
Professor, Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
James de Lemos, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; Regeneron; AstraZeneca
Dr James de Lemos, professor of internal medicine at the University of Texas Southwestern Medical Center, presents a framework to address the most common questions that patients have about the reported muscular, cognitive, and hepatotoxic side effects of statin therapy.
To start, he presents clinical data to address areas of patient concern. Next, he discusses ways to develop — from the first visit — a partnership with patients and encourage their informed decision-making by guiding them to reliable medical sources.
Finally, Dr de Lemos presents strategies that clinicians can use to improve adherence to statin therapy to reach LDL-C treatment goals
--
James de Lemos, MD, PhD
Professor, Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
James de Lemos, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; Regeneron; AstraZeneca
Dr James de Lemos, professor of internal medicine at the University of Texas Southwestern Medical Center, presents a framework to address the most common questions that patients have about the reported muscular, cognitive, and hepatotoxic side effects of statin therapy.
To start, he presents clinical data to address areas of patient concern. Next, he discusses ways to develop — from the first visit — a partnership with patients and encourage their informed decision-making by guiding them to reliable medical sources.
Finally, Dr de Lemos presents strategies that clinicians can use to improve adherence to statin therapy to reach LDL-C treatment goals
--
James de Lemos, MD, PhD
Professor, Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, Texas
James de Lemos, MD, PhD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Amgen; Regeneron; AstraZeneca
